AU1536392A - Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes - Google Patents

Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes

Info

Publication number
AU1536392A
AU1536392A AU15363/92A AU1536392A AU1536392A AU 1536392 A AU1536392 A AU 1536392A AU 15363/92 A AU15363/92 A AU 15363/92A AU 1536392 A AU1536392 A AU 1536392A AU 1536392 A AU1536392 A AU 1536392A
Authority
AU
Australia
Prior art keywords
oncogenes
methods
tumor suppressor
suppressor genes
modulating expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15363/92A
Inventor
J. Gordon Foulkes
Franz Leichtfried
Richard Michitch
Christian Pieler
John Stevenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
Oncogene Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogene Science Inc filed Critical Oncogene Science Inc
Publication of AU1536392A publication Critical patent/AU1536392A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
AU15363/92A 1991-01-18 1992-01-17 Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes Abandoned AU1536392A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64429391A 1991-01-18 1991-01-18
US644293 1991-01-18

Publications (1)

Publication Number Publication Date
AU1536392A true AU1536392A (en) 1992-08-27

Family

ID=24584283

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15363/92A Abandoned AU1536392A (en) 1991-01-18 1992-01-17 Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes

Country Status (2)

Country Link
AU (1) AU1536392A (en)
WO (1) WO1992013091A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650677B2 (en) * 1990-09-24 1994-06-30 General Hospital Corporation, The Screening assays

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445941A (en) * 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
US5843683A (en) * 1993-07-14 1998-12-01 Brandeis University PAS domain proteins
WO1995013375A1 (en) * 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
WO1995016694A1 (en) * 1993-12-16 1995-06-22 Cold Spring Harbor Laboratory Origin of replication complex genes, proteins and methods
US5604113A (en) * 1994-04-07 1997-02-18 Rutgers University Cells having oncogene-suppressed p53-mediated apoptosis and methods of use to identify anti-oncogenic compounds
US5712094A (en) * 1995-03-27 1998-01-27 Ligand Pharmaceuticals, Inc. Methods for detecting modulators of cytokine action
WO1996038176A1 (en) * 1995-06-01 1996-12-05 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonucleotide derivative against wilms' tumor gene (wt1)
US6083690A (en) * 1995-06-02 2000-07-04 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents
US5759776A (en) * 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
WO1997014812A2 (en) * 1995-10-16 1997-04-24 Chiron Corporation Method of screening for factors that modulate gene expression
US5776683A (en) * 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
AU742696B2 (en) * 1996-11-18 2002-01-10 Mcgill University Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth
EP1288311A3 (en) * 1996-12-31 2004-09-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for testing small pharmaceutically active molecules in the activation of Pax4 and production of insulin producing beta-cells
US6413717B1 (en) * 1998-03-18 2002-07-02 Corixa Corporation Methods for indentifying anti-cancer agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535058A (en) * 1982-10-01 1985-08-13 Massachusetts Institute Of Technology Characterization of oncogenes and assays based thereon
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4601978A (en) * 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) * 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US4761371A (en) * 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US4861709A (en) * 1985-05-31 1989-08-29 Technicon Research A.G. Detection and/or identification of microorganisms in a test sample using bioluminescence or other exogenous genetically-introduced marker
US4981783A (en) * 1986-04-16 1991-01-01 Montefiore Medical Center Method for detecting pathological conditions
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US4935363A (en) * 1987-03-30 1990-06-19 Board Of Regents, The University Of Texas System Sterol regulatory elements
US4885238A (en) * 1987-10-30 1989-12-05 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human bronchial epitherial mesothelial cell lines
JPH03502040A (en) * 1987-09-21 1991-05-16 アムラド・コーポレイション・リミテッド Regulation of GM-CSF gene expression
US5070012A (en) * 1988-03-30 1991-12-03 The Board Of Trustees Of The Leland Stanford Junior University Monitoring of cells and trans-activating transcription elements

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650677B2 (en) * 1990-09-24 1994-06-30 General Hospital Corporation, The Screening assays

Also Published As

Publication number Publication date
WO1992013091A1 (en) 1992-08-06

Similar Documents

Publication Publication Date Title
AU1536392A (en) Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes
KR960700752A (en) Extensive tumor suppressor genes and gene products and methods of tumor suppressor gene therapy
AU3665893A (en) Sequences characteristic of human gene transcription product
AU5044393A (en) Stereoselective reduction of ketones
AU3249793A (en) Compositions and methods for modulating beta -amyloid
AU5669494A (en) Human homolog of the e-cadherin gene and methods based thereon
EP0772678A4 (en) Modulation of drug radiation resistant genes
GB9119338D0 (en) Control of gene expression
AU1469292A (en) Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes
AU3937593A (en) Trans-sialidase and methods of use and making thereof
AU6226894A (en) Implantable therapy systems and methods
AU7720394A (en) Multi-unit ribozyme inhibition of oncogene expression
AU2861892A (en) Astrocyte-specific transcription of human genes
AU1347292A (en) Methods of transcriptionally modulating gene expression of viral genes and other genes
AU6010294A (en) Modulators of gene expression
AU659462B2 (en) Methods for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus
GB9201549D0 (en) Control of gene transcription
AU8427091A (en) Gamma-carboxylase and methods of use
AU1268192A (en) Cloning and expression of tissue transglutaminases
AU4033593A (en) Modulation of thrombospondin-CD36 interactions
AU4118393A (en) Human crabp-I and crabp-II
AU1258292A (en) Methods of transcriptionally modulating expression of hematopoietic growth factor genes
AU3973793A (en) Method of treating cancer
EP0524910A3 (en) Modulation of flower colour
AU4550089A (en) Ultraviolet stabilisation of acrylic polymers